FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087662618> ?p ?o ?g. }

• W3087662618 endingPage "2858" @default.
• W3087662618 startingPage "2853" @default.
• W3087662618 abstract "Approximately 20-50% patients with chronic phase chronic myeloid leukemia (CML-CP) treated with tyrosine kinase inhibitors (TKIs) or with myelofibrosis (MF) treated with ruxolitinib develop grade ≥3 thrombocytopenia needing treatment interruptions and dose reductions. We conducted a non-randomized, phase II, single-arm study to determine the efficacy of eltrombopag for patients with CML or MF with persistent thrombocytopenia while on TKI or ruxolitinib. Eltrombopag was initiated at 50 mg/day, with dose escalation up to 300 mg daily allowed every 2 weeks. Twenty-one patients were enrolled (CML=15, MF=6); median age 60 years (range, 31-97 years). The median platelet count was 44x109/L (range, 3-49x109/L) in CML and 62x109/L (range, 21-75x109/L) in MF. After a median of 18 months (range, 5-77 months), 12/15 patients with CML achieved complete platelet response. The median peak platelet count among responders was 154x109/L (range, 74-893x109/L). Among CML patients 5 could re-escalate the TKI dose and 9 improved their response. None of the 6 patients with MF had a sustained response. Therapy was generally well tolerated. One patient discontinued therapy due to toxicity (elevated transaminases). One patient with CML developed significant thrombocytosis (>1000x109/L). Another CML patient developed non occlusive deep venous thrombosis in the right upper extremity without thrombocytosis, and one MF patient had myocardial infarction. Eltrombopag may help improve platelet counts in CML patients receiving TKI with recurrent thrombocytopenia. Further studies are warranted." @default.
• W3087662618 created "2020-09-25" @default.
• W3087662618 creator A5000750846 @default.
• W3087662618 creator A5015140142 @default.
• W3087662618 creator A5020340537 @default.
• W3087662618 creator A5029750735 @default.
• W3087662618 creator A5044229710 @default.
• W3087662618 creator A5049385583 @default.
• W3087662618 creator A5055045706 @default.
• W3087662618 creator A5059747862 @default.
• W3087662618 creator A5061026876 @default.
• W3087662618 creator A5080350639 @default.
• W3087662618 creator A5083793750 @default.
• W3087662618 creator A5085521139 @default.
• W3087662618 date "2020-09-14" @default.
• W3087662618 modified "2023-10-15" @default.
• W3087662618 title "The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis" @default.
• W3087662618 cites W1981317886 @default.
• W3087662618 cites W1992837198 @default.
• W3087662618 cites W1998560266 @default.
• W3087662618 cites W2008933596 @default.
• W3087662618 cites W2013850642 @default.
• W3087662618 cites W2016406604 @default.
• W3087662618 cites W2039002753 @default.
• W3087662618 cites W2044335440 @default.
• W3087662618 cites W2057058781 @default.
• W3087662618 cites W2075090852 @default.
• W3087662618 cites W2080125373 @default.
• W3087662618 cites W2085342571 @default.
• W3087662618 cites W2086647861 @default.
• W3087662618 cites W2097255369 @default.
• W3087662618 cites W2097799776 @default.
• W3087662618 cites W2115351357 @default.
• W3087662618 cites W2116043577 @default.
• W3087662618 cites W2118152564 @default.
• W3087662618 cites W2121743767 @default.
• W3087662618 cites W2123633897 @default.
• W3087662618 cites W2146658081 @default.
• W3087662618 cites W2147109509 @default.
• W3087662618 cites W2150456410 @default.
• W3087662618 cites W2156145496 @default.
• W3087662618 cites W2166654361 @default.
• W3087662618 cites W2348125190 @default.
• W3087662618 cites W2605781925 @default.
• W3087662618 doi "https://doi.org/10.3324/haematol.2020.260125" @default.
• W3087662618 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8561288" @default.
• W3087662618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33054123" @default.
• W3087662618 hasPublicationYear "2020" @default.
• W3087662618 type Work @default.
• W3087662618 sameAs 3087662618 @default.
• W3087662618 citedByCount "13" @default.
• W3087662618 countsByYear W30876626182021 @default.
• W3087662618 countsByYear W30876626182022 @default.
• W3087662618 countsByYear W30876626182023 @default.
• W3087662618 crossrefType "journal-article" @default.
• W3087662618 hasAuthorship W3087662618A5000750846 @default.
• W3087662618 hasAuthorship W3087662618A5015140142 @default.
• W3087662618 hasAuthorship W3087662618A5020340537 @default.
• W3087662618 hasAuthorship W3087662618A5029750735 @default.
• W3087662618 hasAuthorship W3087662618A5044229710 @default.
• W3087662618 hasAuthorship W3087662618A5049385583 @default.
• W3087662618 hasAuthorship W3087662618A5055045706 @default.
• W3087662618 hasAuthorship W3087662618A5059747862 @default.
• W3087662618 hasAuthorship W3087662618A5061026876 @default.
• W3087662618 hasAuthorship W3087662618A5080350639 @default.
• W3087662618 hasAuthorship W3087662618A5083793750 @default.
• W3087662618 hasAuthorship W3087662618A5085521139 @default.
• W3087662618 hasBestOaLocation W30876626181 @default.
• W3087662618 hasConcept C126322002 @default.
• W3087662618 hasConcept C141071460 @default.
• W3087662618 hasConcept C2776112149 @default.
• W3087662618 hasConcept C2778729363 @default.
• W3087662618 hasConcept C2779788118 @default.
• W3087662618 hasConcept C2780007613 @default.
• W3087662618 hasConcept C2780076729 @default.
• W3087662618 hasConcept C2780588981 @default.
• W3087662618 hasConcept C2780829020 @default.
• W3087662618 hasConcept C2780868729 @default.
• W3087662618 hasConcept C2781057849 @default.
• W3087662618 hasConcept C2993327898 @default.
• W3087662618 hasConcept C71924100 @default.
• W3087662618 hasConcept C89560881 @default.
• W3087662618 hasConcept C90924648 @default.
• W3087662618 hasConceptScore W3087662618C126322002 @default.
• W3087662618 hasConceptScore W3087662618C141071460 @default.
• W3087662618 hasConceptScore W3087662618C2776112149 @default.
• W3087662618 hasConceptScore W3087662618C2778729363 @default.
• W3087662618 hasConceptScore W3087662618C2779788118 @default.
• W3087662618 hasConceptScore W3087662618C2780007613 @default.
• W3087662618 hasConceptScore W3087662618C2780076729 @default.
• W3087662618 hasConceptScore W3087662618C2780588981 @default.
• W3087662618 hasConceptScore W3087662618C2780829020 @default.
• W3087662618 hasConceptScore W3087662618C2780868729 @default.
• W3087662618 hasConceptScore W3087662618C2781057849 @default.
• W3087662618 hasConceptScore W3087662618C2993327898 @default.
• W3087662618 hasConceptScore W3087662618C71924100 @default.
• W3087662618 hasConceptScore W3087662618C89560881 @default.
• W3087662618 hasConceptScore W3087662618C90924648 @default.

• next